title: Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review.
abstract: Fusarium species are the second leading cause of disseminated mold infections in immunocompromised patients. The high mortality caused by such infections is attributed to the high resistance of Fusarium species to current antifungal agents. We report the first case of disseminated fusariosis after the use of alemtuzumab, an anti-CD52 monoclonal antibody, in a patient who presented with striking cutaneous and oral cavity lesions. Case reports of combination antifungal therapy for disseminated fusariosis in immunocompromised patients were reviewed. Among 19 published cases in the last 10 years plus this patient, the patients in 14 cases (70%) responded positively to combination antifungal therapy. A clinical response was achieved in seven cases before resolution of neutropenia.
authors: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
authors: Jyh-You
authors: JY
authors: Liu
authors: Wei-Ting
authors: WT
authors: Chen
authors: Bor-Sheng
authors: BS
authors: Ko
authors: Ming
authors: M
authors: Yao
authors: Po-Ren
authors: PR
authors: Hsueh
authors: Cheng-Hsiang
authors: CH
authors: Hsiao
authors: Yu-Min
authors: YM
authors: Kuo
authors: Yee-Chun
authors: YC
authors: Chen
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003840:Deoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005334:Fever; D060585:Fusariosis / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D005670:Fusarium / Q000166:cytology / Q000187:drug effects / Q000302:isolation & purification*; D006098:Granulocytes; D006801:Humans; D016867:Immunocompromised Host; D017708:Leukocyte Transfusion; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D009503:Neutropenia; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D004338:Drug Combinations; D011743:Pyrimidines; D014230:Triazoles; D003840:Deoxycholic Acid; D000074323:Alemtuzumab; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination; D065819:Voriconazole